The Journal of urology
-
The Journal of urology · Nov 2013
Randomized Controlled TrialPerioperative celecoxib decreases opioid use in patients undergoing testicular surgery: a randomized, double-blind, placebo controlled trial.
We evaluated the effect of daily perioperative celecoxib on patient reported pain control and opioid use after testicular surgery. ⋯ Twice daily celecoxib use started preoperatively significantly decreased patient reported postoperative pain and opioid use, especially in the early postoperative period. A short course of celecoxib is well tolerated and may be effective as part of multimodal postoperative analgesia in patients who undergo testicular surgery for sperm retrieval.
-
The Journal of urology · Oct 2013
Randomized Controlled TrialImproving patient knowledge about sacral nerve stimulation using a patient based educational video.
We developed a patient based educational video to address the information needs of women considering sacral nerve stimulation for overactive bladder. ⋯ Women with overactive bladder considering sacral nerve stimulation therapy have specific information needs. The video that we developed to address these needs was associated with improved short-term patient knowledge.
-
The Journal of urology · Oct 2013
Randomized Controlled TrialUrodynamics and safety of the β₃-adrenoceptor agonist mirabegron in males with lower urinary tract symptoms and bladder outlet obstruction.
Bladder outlet obstruction often presents as storage and voiding symptoms. We investigated urodynamic parameters in men with lower urinary tract symptoms and bladder outlet obstruction treated with the β₃ agonist mirabegron, a new therapy for overactive bladder symptoms. ⋯ Mirabegron did not adversely affect voiding urodynamics (maximum urinary flow and detrusor pressure at maximum urinary flow) compared with placebo after 12 weeks of treatment.
-
The Journal of urology · Sep 2013
Randomized Controlled Trial Multicenter Study Comparative StudyThe impact of intravesical gemcitabine and 1/3 dose Bacillus Calmette-Guérin instillation therapy on the quality of life in patients with nonmuscle invasive bladder cancer: results of a prospective, randomized, phase II trial.
Bacillus Calmette-Guérin and intravesical chemotherapy represent viable adjuvant options for intermediate risk nonmuscle invasive bladder cancer. Although bacillus Calmette-Guérin is perceived as less tolerable than intravesical chemotherapy, to our knowledge no comparative studies have addressed quality of life issues. We compared the quality of life of patients with nonmuscle invasive bladder cancer who received adjuvant intravesical gemcitabine or 1/3 dose bacillus Calmette-Guérin. ⋯ While a higher rate of side effects, albeit mild to moderate, was detected with 1/3 dose bacillus Calmette-Guérin compared to gemcitabine, our study failed to show significant differences between the 2 drugs in terms of quality of life.
-
The Journal of urology · Jul 2013
Randomized Controlled Trial Comparative StudyRoutine flexible nephroscopy for percutaneous nephrolithotomy for renal stones with low density: a prospective, randomized study.
We evaluated the usefulness of routine flexible nephroscopy during percutaneous nephrolithotomy. ⋯ Routine flexible nephroscopy during percutaneous nephrolithotomy was associated with a higher stone-free rate, fewer interventions and less bleeding, especially in patients with low HU density stones.